UB Paderborn / Katalog / Suche / in CDI

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood, 2014-01, Vol.123 (3), p.317-325

2014

Volltextzugriff (PDF)

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

Journal of thrombosis and haemostasis, 2017-03, Vol.15 (3), p.411-419

2017

Volltextzugriff (PDF)

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Journal of thrombosis and haemostasis, 2012-08, Vol.10 (8), p.1581-1590

2012

Volltextzugriff (PDF)

Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-07, Vol.23 (4), p.566-574

2017

Volltextzugriff (PDF)

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)

Journal of thrombosis and haemostasis, 2005-03, Vol.3 (3), p.459-464

2005

Volltextzugriff (PDF)

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.72-80

2016

Volltextzugriff (PDF)

A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

Journal of thrombosis and haemostasis, 2012-03, Vol.10 (3), p.359-367

2012

Volltextzugriff (PDF)

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.e259-e266

2016

Volltextzugriff (PDF)

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Blood, 2016-04, Vol.127 (14), p.1761-1769

2016

Volltextzugriff (PDF)

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Journal of thrombosis and haemostasis, 2009-03, Vol.7 (3), p.413-420

2009

Volltextzugriff (PDF)

Recurrence rate after a first venous thrombosis in patients with familial thrombophilia

Arteriosclerosis, thrombosis, and vascular biology, 2005-09, Vol.25 (9), p.1992

2005

Volltextzugriff (PDF)

Inhibitor development and mortality in non‐severe hemophilia A

Journal of thrombosis and haemostasis, 2015-07, Vol.13 (7), p.1217-1225

2015

Volltextzugriff (PDF)

Mortality and inherited thrombophilia: results from the European Prospective Cohort on Thrombophilia

Journal of thrombosis and haemostasis, 2012-02, Vol.10 (2), p.217-222

2012

Volltextzugriff (PDF)

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Journal of thrombosis and haemostasis, 2010-04, Vol.8 (4), p.730-736

2010

Volltextzugriff (PDF)

The bleeding phenotype in people with nonsevere hemophilia

Blood advances, 2022-07, Vol.6 (14), p.4256-4265

2022

Volltextzugriff (PDF)

Spectrum of causative mutations in patients with haemophilia A in Austria

Thrombosis and haemostasis, 2010-07, Vol.104 (1), p.78

2010

Volltextzugriff (PDF)

Haemophilia Care in Europe: the ESCHQoL study

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-09, Vol.18 (5), p.729-737

2012

Volltextzugriff (PDF)

Treatment of primary autoimmune thrombocytopenia (AITP) [1]

Vox sanguinis, 2012-04, Vol.102 (3), p.261-268

2012

Volltextzugriff (PDF)

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (5), p.428-437

2004

Volltextzugriff (PDF)

Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-05, Vol.20 (3), p.354-361

2014

Volltextzugriff (PDF)

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Expert opinion on biological therapy, 2009-03, Vol.9 (3), p.273-283

2009

Volltextzugriff (PDF)

Specificities of Platelet Autoantibodies and Platelet Activation in Lupus Anticoagulant Patients: A Relation to their History of Thromboembolic Disease

Lupus, 2006-01, Vol.15 (8), p.507-514

2006

Volltextzugriff (PDF)

No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene

Blood coagulation & fibrinolysis, 1999-03, Vol.10 (2), p.101-106

1999

Volltextzugriff (PDF)

Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts

Hämostaseologie, 2009-05, Vol.29 (2), p.197

2009

Volltextzugriff (PDF)

High risk of acquired immune deficiency syndrome (AIDS) and of AIDS related complex (ARC) in hemophiliacs seropositive for more than 5 years

Thrombosis and haemostasis, 1989-06, Vol.61 (3), p.354

1989

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Recurrence rate after a first venous thrombosis in patients with familial thrombophilia

Inhibitor development and mortality in non‐severe hemophilia A

Mortality and inherited thrombophilia: results from the European Prospective Cohort on Thrombophilia

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

The bleeding phenotype in people with nonsevere hemophilia

Spectrum of causative mutations in patients with haemophilia A in Austria

Haemophilia Care in Europe: the ESCHQoL study

Treatment of primary autoimmune thrombocytopenia (AITP) [1]

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Specificities of Platelet Autoantibodies and Platelet Activation in Lupus Anticoagulant Patients: A Relation to their History of Thromboembolic Disease

No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene

Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts

High risk of acquired immune deficiency syndrome (AIDS) and of AIDS related complex (ARC) in hemophiliacs seropositive for more than 5 years

Aktive Filter

Suchergebnisse filtern